Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Cash from Financing Activities (2019 - 2025)

Historic Cash from Financing Activities for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $236.0 million.

  • Nurix Therapeutics' Cash from Financing Activities rose 1769.74% to $236.0 million in Q4 2025 from the same period last year, while for Nov 2025 it was $238.6 million, marking a year-over-year decrease of 5086.3%. This contributed to the annual value of $238.6 million for FY2025, which is 5086.3% down from last year.
  • Nurix Therapeutics' Cash from Financing Activities amounted to $236.0 million in Q4 2025, which was up 1769.74% from $1.2 million recorded in Q3 2025.
  • Nurix Therapeutics' 5-year Cash from Financing Activities high stood at $237.8 million for Q2 2024, and its period low was -$135000.0 during Q4 2022.
  • Its 5-year average for Cash from Financing Activities is $49.9 million, with a median of $1.5 million in 2022.
  • As far as peak fluctuations go, Nurix Therapeutics' Cash from Financing Activities tumbled by 12700.0% in 2022, and later surged by 286448571.43% in 2024.
  • Nurix Therapeutics' Cash from Financing Activities (Quarter) stood at $500000.0 in 2021, then plummeted by 127.0% to -$135000.0 in 2022, then skyrocketed by 105.19% to $7000.0 in 2023, then surged by 2864485.71% to $200.5 million in 2024, then rose by 17.7% to $236.0 million in 2025.
  • Its Cash from Financing Activities was $236.0 million in Q4 2025, compared to $1.2 million in Q3 2025 and $6000.0 in Q2 2025.